SCHEMBL2033666

SCHEMBL2033666

COC(=O)c1ccc(N)c(OC(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.54
KDM4E B2RXH2 7/20 0.53
MAPT P10636 6/20 0.53
ALDH1A1 P00352 6/20 0.53
HPGD P15428 5/20 0.53
GAA P10253 3/20 0.53
HSD17B10 Q99714 2/20 0.53
GLA P06280 1/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
ATM Q13315 1/20 0.53
USP2 O75604 1/20 0.49
MRGPRX4 Q96LA9 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
XDH P47989 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31003812 1.00 NOTUM (0.54) NOTUMKDM4EMAPTALDH1A1HPGD
Hydrochloric Acid SCHEMBL2241815 0.98 NOTUM (0.52) NOTUMKDM4EMAPTALDH1A1HPGD
SCHEMBL7361708 0.88 USP2 (0.60) NOTUMKDM4EMAPTALDH1A1HPGD
SCHEMBL13733615 0.84 CYP1A2 (0.51) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL13175556 0.83 SLC6A2 (0.49) HPGDHDAC1SMN1; SMN2PDK2HTT
SCHEMBL16335478 0.83 NOTUM (0.76) NOTUMKDM4EMAPTALDH1A1HPGD
SCHEMBL10321468 0.83 CA12 (0.59) NOTUMKDM4EMAPTALDH1A1HPGD
SCHEMBL14317068 0.83 MAPT (0.64) NOTUMKDM4EMAPTALDH1A1GLA
SCHEMBL1110800 0.83 NOTUM (0.58) NOTUMKDM4EMAPTALDH1A1HPGD
SCHEMBL12970641 0.82 SLC6A2 (0.46) ALDH1A1L3MBTL1MAPK1KMT2APDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509470-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2025-12-30 US disclosed
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 US disclosed
US-20240382471-A1 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF Hepagene Therapeutics (HK) Limited (CN) 2024-11-21 US disclosed
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 EP disclosed
US-12006326-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2024-06-11 US disclosed
CN-118076607-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2024-05-24 CN disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
CN-117715906-A Glucagon-like peptide-1 receptor modulators and uses thereof 和博医药有限公司 2024-03-15 CN disclosed
CN-111655680-B Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders 阿德利克斯股份有限公司 2024-03-05 CN disclosed
CN-116854681-A Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2023-10-10 CN disclosed
US-20090163552-A1 CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-06-25 US disclosed
WO-2009024615-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2009-02-26 WO disclosed
US-20090054427-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS BRIARD EMMANUELLE 2009-02-26 US disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed
US-7067506-B2 Compounds useful for inhibiting Chk1 ICOS CORPORATION (US) 2006-06-27 US disclosed
US-20050245525-A1 Compounds useful for inhibiting CHK1 ICOS CORPORATION (US) 2005-11-03 US disclosed
EP-1379510-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2004-01-14 EP disclosed
US-20030069284-A1 Compounds useful for inhibiting Chk1 ICOS CORPORATION (A WASHINGTON CORPORATION) 2003-04-10 US disclosed
WO-2002070494-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245525-A1 Compounds useful for inhibiting CHK1 CHEK1, PCNA, CHEK2 NOTUM 3034/4885KDM4E 2395/4885MAPT 3233/4885
US-12509470-B2 Antiviral heterocyclic compounds NR3C1, ZC3HAV1, HAVCR2 NOTUM 4563/4885KDM4E 3773/4885MAPT 4847/4885
US-20240382471-A1 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF GLP1R, GIPR, GCGR NOTUM 2026/4885KDM4E 3593/4885MAPT 4014/4885
US-20090054427-A1 AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS BACE2, BACE1, APP NOTUM 376/4885KDM4E 1305/4885MAPT 49/4885
US-20030069284-A1 Compounds useful for inhibiting Chk1 CHEK1, PCNA, CHEK2 NOTUM 3034/4885KDM4E 2395/4885MAPT 3233/4885
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 NOTUM 3646/4885KDM4E 1918/4885MAPT 2055/4885
US-12006326-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 NOTUM 821/4885KDM4E 1648/4885MAPT 4608/4885
US-20090163552-A1 CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES NR1H4, GPBAR1, SLC10A1 NOTUM 1231/4885KDM4E 2127/4885MAPT 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.